You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

781 Results
Lung cancer screening through the Ontario Lung Screening Program is available for people who qualify at the following hospitals in Ontario. People...
The Ontario Cancer Registry SEER*Stat Package contains de-identified Ontario cancer data files derived from the Ontario Cancer Registry, the SEER*...
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal
Intent: Palliative
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal
Intent: Palliative
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal
Intent: Palliative
Funding:
New Drug Funding Program
    Nivolumab plus Ipilimumab - MSI-H/dMMR Locally Advanced Unresectable or Metastatic Colorectal Cancer
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - Locally Recurrent Unresectable or Metastatic Triple Negative Breast Cancer
New Drug Funding Program
    Nab-Paclitaxel - Metastatic Breast Cancer
Drug
Oct 2023
Drug
Other Name(s): Opdivo®
Jan 2026
Guidelines and Advice
Dec 1969
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Nivolumab - Advanced Melanoma (Unresectable or Metastatic Melanoma)
Updated
Mar 2026
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Nivolumab plus Ipilimumab - Advanced Melanoma (Unresectable or Metastatic Melanoma)
New Drug Funding Program
    Nivolumab plus Ipilimumab - Advanced Melanoma (Unresectable or Metastatic Melanoma)
Updated
Mar 2026

Pages